Alendronate Na Salt (Wako Catalog No. 012-22661 (100 mg); 018-22663 (500 mg))
Resedronate Na Salt (Wako Catalog No. 189-02461 (100 mg); 185-02463 (500
mg))
Bone tissue is being remodeled by continuous deossification and ossification. The number of patients with osteoporosis caused by imbalance in the bone metabolism is increasing with the transition to an aging society. This product is a bisphosphonate compound that is selectively distributed in the calcified bone surface to which the osteoclasts are attached. It is released under an acid environment created by the osteoclasts, taken in the cells, and inhibits the bone resorption activity. The inhibition of the bone resorption is considered to be caused by apoptosis induction effect of the osteoclasts and direct suppression of bone resorption of the osteoclasts.
Products
Alendronate Na Salt TrihydrateAssay (HPLC): 97.0+ %
Solubility in water: 0.1 g/10 mL
CAS No. : 121268-17-5
Risedronate Na Salt n-HydrateAssay (HPLC): 97.0+ %
Solubility in water: 0.1 g/10 mL
CAS No. : 115436-72-1
Structural Formula
Alendronate Sodium Salt Trihydrate
Risedronate Sodium Salt n-Hydrate
Product List
Osteoclastic Inhibitors
|
|
|
|
|
|
|
|
|
Related Product
for enzyme activity staining of tartrate-resistant acid phosphatase and
alkaline phosphatase
|
|
|
|
|
|
